Revolutionizing Drug Delivery: Oral Proteins and Peptides Market Forecast to Hit USD 37.77 Billion by 2033

According to the latest research by Straits Research, the Global Oral Proteins and Peptides Market is on an impressive growth trajectory. Valued at USD 7.13 billion in 2024, the market is projected to increase from USD 8.58 billion in 2025 to USD 37.77 billion by 2033, expanding at a robust CAGR of 20.35% during the forecast period (2025-2033).

This strong growth underscores the healthcare industry's ongoing transformation toward non-invasive, patient-friendly drug delivery methods, particularly for chronic and metabolic diseases.

Get The Full Report With Trends & Forecasts: https://straitsresearch.com/report/oral-proteins-and-peptides-market

Market Overview: The Shift Toward Oral Biologics
The rapid evolution of biopharmaceutical innovation is propelling the oral proteins and peptides market to new heights. With growing patient preference for non-invasive therapies over injectables, pharmaceutical companies are investing heavily in oral drug formulations that offer better compliance and convenience.

Oral biologics are gaining significant traction as researchers develop new techniques to improve drug absorption, bioavailability, and stability. This shift not only enhances treatment outcomes but also opens new therapeutic avenues for managing chronic conditions like diabetes, gastrointestinal disorders, and metabolic diseases.

In addition, rising healthcare expenditures, an aging global population, and favorable regulatory pathways for oral biologics are accelerating adoption and commercialization worldwide.

Latest Market Trends: Breakthroughs in Oral Delivery Technology
One of the most exciting trends reshaping the industry is the advancement in oral delivery technologies. Innovations such as nanoparticles, microemulsions, and self-emulsifying drug delivery systems (SEDDS) are redefining how biologics can be administered effectively via the oral route.

A 2024 study published in Science Advances highlighted a revolutionary ionic liquid-based nanocarrier designed to protect insulin from stomach degradation while improving intestinal absorption. This breakthrough could drastically reduce the need for injections among diabetic patients, representing a major milestone in oral biologic drug delivery.

Similarly, lipid-based nanoparticles and SEDDS are enabling controlled release mechanisms, enhancing therapeutic efficacy, and improving patient compliance further strengthening the commercial viability of oral peptide and protein drugs.

Market Growth Drivers
1. Rising Prevalence of Chronic Diseases
The global burden of chronic diseases continues to rise due to factors such as sedentary lifestyles, poor diet, and aging populations. According to the World Health Organization (WHO), chronic diseases like diabetes, cardiovascular ailments, and cancer account for over 75% of global deaths annually.
This surge in chronic illness has created immense demand for targeted biologics and oral peptide-based therapies that offer safer, more convenient treatment options. Pharmaceutical companies are increasingly focusing on AI-driven diagnostics, personalized medicine, and advanced drug delivery systems to meet these growing needs.

2. Regulatory Support and Investment in R&D
Regulatory bodies such as the U.S. FDA and the European Medicines Agency (EMA) are supporting clinical research and approving innovative oral biologics at a faster pace. Combined with expanding investments in biotech R&D, this regulatory backing is creating an environment conducive to rapid innovation and commercialization.

Market Challenges: Low Bioavailability Remains a Key Restraint
Despite strong momentum, the oral proteins and peptides market faces significant technical challenges, particularly related to low bioavailability. The gastrointestinal tract presents natural barriers that hinder drug absorption, such as enzymatic degradation, acidic conditions, and poor permeability of large biomolecules.

Typically, oral biologics exhibit less than 2% bioavailability, necessitating complex formulation technologies and higher dosages to achieve desired therapeutic effects. This limitation increases R&D costs and delays commercialization, although ongoing advancements in nanocarrier design and permeability enhancers are gradually overcoming these hurdles.

Get Your Free Sample Report: https://straitsresearch.com/report/oral-proteins-and-peptides-market/request-sample

Emerging Opportunities: Expanding Therapeutic Applications
The market is witnessing exciting opportunities in new therapeutic areas, including Non-Alcoholic Steatohepatitis (NASH) and Alzheimer's disease.

A 2024 study in Brain Research introduced PHDP5, a synthetic peptide that targets tau protein buildup in Alzheimer's disease. The peptide showed promise in reversing memory and learning deficits in preclinical models, signaling a potential revolution in neurodegenerative disease therapy.

Similarly, peptides are showing efficacy in metabolic and liver disorders, offering non-invasive, effective solutions for complex diseases that previously required injectables.

Regional Insights: North America Leads, Asia-Pacific Rising
North America
North America remains a leader in the oral proteins and peptides market, thanks to advanced pharmaceutical R&D infrastructure, high healthcare expenditure, and the rapid adoption of novel drug delivery systems.
The U.S. market is spearheading growth, with products like Novo Nordisk's Rybelsus (oral GLP-1 analog) gaining substantial traction. Meanwhile, Canada continues to expand its presence with robust biotech collaborations and government-backed innovation hubs.

Asia-Pacific
Asia-Pacific is emerging as a high-growth region, driven by rising chronic disease prevalence, expanding healthcare infrastructure, and strong pharmaceutical manufacturing capabilities.
Countries like China and India are investing heavily in oral insulin research, biotech innovation, and nanoparticle-based delivery systems, with domestic firms such as Biocon and Jiangsu Hansoh Pharmaceutical at the forefront.

Europe
Europe's market growth is supported by strong biopharmaceutical research, favorable reimbursement policies, and a supportive regulatory environment. Key players in Germany and the UK including BioNTech, Evotec, and Midatech Pharma are pioneering peptide stabilization and absorption technologies for oral biologics.

Competitive Landscape: Leading Innovators
Prominent players driving innovation in the global oral proteins and peptides market include:
Novo Nordisk A/S, Johnson & Johnson Services Inc., Oramed Pharmaceuticals Inc., Rani Therapeutics, Biocon Limited, Allergan plc, Enteris BioPharma Inc., Ipsen Pharma, Chiasma Inc., and Protagonist Therapeutics Inc.

These companies are focusing on drug delivery innovation, strategic collaborations, and clinical trial expansion to overcome absorption challenges and bring next-generation oral biologics to market.

In March 2025, Johnson & Johnson's Icotrokinra (oral IL-23R peptide) achieved remarkable Phase 3 results for plaque psoriasis, showing clear or almost clear skin in 65% of patients by Week 16 a major milestone in peptide therapeutics.

Conclusion: The Future of Non-Invasive Therapeutics
As innovation accelerates, the oral proteins and peptides market is set to redefine modern medicine. By addressing bioavailability challenges and expanding therapeutic applications, this market promises to make biologics more accessible, affordable, and patient-friendly than ever before.
With a projected market value of USD 37.77 billion by 2033, the next decade will mark a turning point for oral biologics transforming how chronic diseases are treated across the globe.

Contact Us :
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

About Us :
Straits Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision-makers. Straits Research Pvt. Ltd. provides actionable market research data, especially designed and presented for decision making and ROI.

This release was published on openPR.